Christoph Nienaber | Cardiovascular Medicine | Excellence in Academia Award

Excellence in Academia Award

Christoph Nienaber
Affiliation Royal Brompton and Harefield Hospitals
Country United Kingdom
Scholar ID pWDqkeQAAAAJ
Documents 1435
Citations 76,690
h-index 121
Subject Area Physical Activity
Event Global Academic Awards

Christoph Nienaber
Royal Brompton and Harefield Hospitals

Christoph Nienaber has established an internationally recognized academic profile through an extensive publication record, substantial citation impact, and continued contributions to cardiovascular medicine and clinical research. His scholarly influence is reflected through widely cited publications, interdisciplinary collaboration, and long-term engagement in evidence-based medical science.[1]

Abstract

Christoph Nienaber has developed an extensive academic career characterized by high-impact research, broad international collaboration, and significant scientific influence. Bibliometric indicators, including more than 1,400 indexed publications, over 76,000 citations, and an h-index exceeding one hundred, demonstrate sustained scholarly productivity and lasting academic impact. These indicators support recognition for long-term excellence in research and higher education.[1]

Keywords

  • Academic Excellence
  • Cardiovascular Medicine
  • Clinical Research
  • Evidence-Based Medicine
  • Scientific Leadership
  • Research Impact

Introduction

Academic excellence encompasses sustained scientific productivity, innovation, mentorship, and contributions that influence research, education, and clinical practice. Recognition through academic awards acknowledges individuals whose scholarly achievements have advanced knowledge within their respective disciplines and contributed to global scientific development.[2]

Research Profile

Christoph Nienaber is affiliated with Royal Brompton and Harefield Hospitals in the United Kingdom. His Google Scholar profile reports approximately 1,435 scholarly publications, over 76,690 citations, and an h-index of 121. These bibliometric measures illustrate exceptional academic productivity and a substantial influence on contemporary cardiovascular research.[1]

Research Contributions

  • Advancement of cardiovascular medicine and clinical cardiology.
  • Leadership in translational and evidence-based clinical research.
  • Extensive peer-reviewed scientific publications.
  • International collaboration and multidisciplinary research initiatives.
  • Contribution to clinical guidelines and medical education.

Publications

The researcher’s publication portfolio spans cardiovascular medicine, vascular diseases, clinical imaging, intervention, and translational healthcare research. Numerous articles have appeared in internationally recognized peer-reviewed journals and continue to receive substantial scholarly citations.[1]

Research Impact

High publication output combined with extensive citation performance demonstrates enduring scientific influence. The researcher’s work has contributed to clinical decision-making, medical education, and continued advancement of cardiovascular science through internationally recognized scholarly communication.[1]

Award Suitability

Based on publicly available bibliometric indicators and documented scholarly achievements, Christoph Nienaber demonstrates the characteristics commonly associated with recipients of academic excellence awards, including sustained publication productivity, exceptional citation impact, international scientific visibility, and long-term contributions to research and higher education. Final award determinations remain subject to independent evaluation by the awarding organization.[3]

Conclusion

Christoph Nienaber’s extensive scholarly record reflects sustained academic excellence, influential research, and meaningful contributions to cardiovascular medicine. His long-standing commitment to scientific inquiry, publication, and international collaboration illustrates the qualities recognized through the Excellence in Academia Award.

References

  1. Google Scholar. (n.d.). Author profile: Christoph Nienaber.
    https://scholar.google.com/citations?user=pWDqkeQAAAAJ&hl=en&oi=sra
  2. Aortic Diameter β‰₯5.5 cm Is Not a Good Predictor of Type A Aortic Dissection: Observations From the International Registry of Acute Aortic Dissection (IRAD).
    https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.107.702720
  3. Randomized Comparison of Strategies for Type B Aortic Dissection: The INvestigation of STEnt Grafts in Aortic Dissection (INSTEAD) Trial.
    https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.109.886408

 

Alperen Taş | Cardiology | Best Researcher Award

Dr. Alperen Taş | Cardiology | Best Researcher Award

Ahi Evran University | Turkey

Dr. Alperen Taş is an emerging cardiology researcher whose work centers on acute heart failure, coronary syndromes, inflammatory biomarkers, prognostic scoring systems, and no-reflow phenomena. He focuses on developing and validating clinical biomarkers and risk-prediction models that enhance early diagnosis, guide clinical decisions, and improve mortality prediction in high-risk cardiac patients. His peer-reviewed contributions span key diagnostic tools, including the Scottish Inflammatory Prognostic Score, prognostic nutritional index, QT interval–GRACE score integration, intracoronary ECG, HALP score, Osaka Prognostic Score, and novel biomarkers such as PDGF-BB, chemerin, and derived NLR. His collaborative studies explore infective endocarditis, myocardial infarction, coronary no-reflow, heart failure progression, echocardiographic functional assessment, and medication-related cardiovascular effects. He has shared his findings at national cardiology congresses, advancing scientific dialogue on inflammatory markers and cardiovascular prognostication. With 12 publications, 24 citations, and an h-index of 2, Dr. Alperen Taş demonstrates solid developing research impact, strong collaboration, and a promising trajectory in preventive cardiology and biomarker-based risk stratification.

Profile: Scopus

Featured Publications

Taş, A., Tunca, Γ‡., TanΔ±k, V. O., & Γ–zlek, B. (2025). The Scottish inflammatory prognostic score: A novel biomarker for predicting in-hospital mortality in acute heart failure with reduced ejection fraction. Heart & Lung, 74, 291–299.

Vincenzo Ezio Santobuono | Cardiovascular Disease | Innovative Research Award

Prof. Vincenzo Ezio Santobuono | Cardiovascular Disease | Innovative Research Award

University of Bari Aldo Moro | Italy

Prof. Vincenzo Ezio Santobuono is an accomplished cardiologist and academic with a Classical High School Diploma (1999), a Degree in Medicine and Surgery from the University of Bari (2006, summa cum laude), a Specialization in Cardiology (2011, summa cum laude), and a PhD in Experimental and Forensic Medicine and Pathology (2015). He has built a distinguished career combining clinical expertise, academic leadership, and pioneering research in cardiology, particularly in telecardiology, remote monitoring, arrhythmia management, and cardiac resynchronization therapy. Professionally, he has served as Medical Director at the Regional TeleCardiology Center of Bari, specialist consultant for military and governmental institutions, and lecturer at the University of Bari β€œAldo Moro” across nursing, medicine, radiology, psychiatric rehabilitation, and cardiovascular disease programs. Currently, he is a fixed-term researcher (RTD-A) leading an innovative project on telecardiology integration within hospital-territory networks. His academic impact is reflected in Scopus metrics with 502 citations, 52 indexed documents, and an h-index of 11, alongside numerous high-impact publications and a patent on supraventricular arrhythmia treatment. Fluent in English and Italian, he actively contributes to cardiovascular innovation, bridging advanced clinical practice with technological solutions to improve patient-centered care and healthcare delivery.

Profile: Scopus | Orcid

Featured Publications

  • Santobuono, V. E., et al. (2025). NPPA-associated atrial dilated cardiomyopathy: Genotypic and phenotypic insights from an ultrarare inherited disorder.

  • Santobuono, V. E., et al. (2025). Differentiating sensor changes in a composite heart failure ICD monitoring index: Clinical correlates and implications.

  • Santobuono, V. E., et al. (2025). Association between device-detected subclinical atrial fibrillation and diabetes in patients with implantable cardioverter-defibrillators: A propensity score-matched analysis. International Journal of Cardiology.

  • Santobuono, V. E., et al. (2025). Kinetics of procalcitonin, CRP, IL-6, and presepsin in heart transplant patients undergoing induction with thymoglobulin (rATG). Journal of Clinical Medicine.

  • Santobuono, V. E., et al. (2025). Dynamic evaluation of atrial fibrillation risk factors using multiple sensors of implantable cardioverter defibrillators.

Shixun Wang | Cardiology | Best Researcher Award

Dr. Shixun Wang | Cardiology | Best Researcher Award

Professor at Weifang People’s Hospital, China

Dr. Wang Shixun πŸ‘¨β€βš•οΈ, born in October 1979, is a distinguished cardiovascular specialist at Weifang People’s Hospital. He earned his doctorate in Cardiovascular Medicine from Weifang Medical College in 2006 and has over 18 years of clinical experience. Currently serving as Deputy Director, he is applying for the position of Chief Physician πŸ‘¨β€πŸ”¬. Known for his excellence in clinical practice, he received top evaluation ratings from 2018 to 2021 🌟. Dr. Wang demonstrates strong computer and foreign language skills πŸ’»πŸ—£οΈ and is highly respected for his dedication to cardiovascular care and hospital leadership ❀️πŸ₯.

Publication Profile

Scopus

Orcid

Academic Background

Dr. Wang Shixun πŸ‘¨β€βš•οΈ graduated from Weifang Medical College in July 2006 πŸŽ“, earning his doctorate in Cardiovascular Medicine ❀️. Immediately after graduation, he began his medical career at Weifang People’s Hospital πŸ₯, demonstrating a seamless transition from academic training to clinical practice. With a strong foundation in medical education and a passion for patient care πŸ’‰, Dr. Wang quickly established himself as a dedicated healthcare professional. His long-term commitment to the same institution reflects both loyalty and deep institutional knowledge πŸ“˜, making him a valuable asset to the hospital and the broader medical community 🌟.

Professional Experience

Dr. Wang Shixun πŸ‘¨β€βš•οΈ obtained his current professional and technical qualifications in March 2017 and has since shown remarkable growth in the field of Cardiovascular Medicine ❀️. He was first appointed to his current role in September 2018 and has accumulated five years of dedicated service in this position. Dr. Wang now applies for the title of Chief Physician, reflecting his advanced clinical expertise and leadership readiness 🧠. He also serves as Deputy Director πŸ₯, balancing administrative responsibilities with medical duties. Additionally, he has demonstrated proficiency in computer applications πŸ’», enhancing his effectiveness in modern healthcare delivery.

Awards and Honors

Dr. Wang Shixun πŸ‘¨β€βš•οΈ has consistently demonstrated excellence in his medical career, earning outstanding performance evaluations for four consecutive yearsβ€”2018, 2019, 2020, and 2021 πŸ…. These “Excellent” ratings reflect his dedication, clinical skill, and strong work ethic in the field of Cardiovascular Medicine ❀️. In 2022, he continued to maintain a high standard with a “Qualified” rating βœ…. His consistent recognition by peers and superiors underscores his commitment to medical excellence and patient care πŸ™Œ. These honors highlight Dr. Wang’s growing influence and leadership within the hospital and the broader medical community πŸ₯✨.

Research Focus

Dr. Wang Shixun πŸ‘¨β€βš•οΈ is deeply engaged in the field of Cardiovascular Medicine, with a strong focus on clinical research aimed at improving patient outcomes and advancing treatment strategies for heart-related conditions β€οΈπŸ«€. His work emphasizes evidence-based practices, integrating the latest medical advancements into routine care πŸ§¬πŸ“Š. As Deputy Director at Weifang People’s Hospital πŸ₯, he actively participates in research initiatives and fosters a collaborative environment for innovation and knowledge sharing πŸ€πŸ’‘. With his solid academic foundation and practical experience, Dr. Wang continues to explore new frontiers in cardiovascular healthcare to benefit patients and the medical community πŸŒπŸ“š.

Publication Top Notes

πŸ“ A Case of Treatment With a Combination of Covered Stents and Artificial Blood Vessel for Iliac Artery Rupture During Transcatheter Aortic Valve Replacement

πŸ“… Year: 2025 | πŸ“š Journal: Clinical Case Reports

Efficacy and Safety of Different Dosing Regimens of Colchicine in Patients with Coronary Artery Disease: A Network Meta-analysis of 15 Randomized Controlled Trials

Effect of levocarnitine on TIMP-1, ICAM-1 expression of rats with coronary heart disease and its myocardial protection effect

Serum Amyloid a Promotes Visfatin Expression in Macrophages

Plumbagin mediates cardioprotection against myocardial ischemia/reperfusion injury through Nrf-2 signaling

Conclusion

Dr. Wang Shixun is a highly skilled and experienced medical professional in the field of Cardiovascular Medicine, currently serving as Deputy Director at Weifang People’s Hospital and applying for the position of Chief Physician. With a doctoral degree and nearly two decades of clinical service since 2006, he has consistently demonstrated excellence, as reflected in multiple years of outstanding evaluations. He also shows proficiency in foreign languages and computer applications. However, while his clinical credentials and leadership are commendable, there is currently limited evidence of significant research contributionsβ€”such as peer-reviewed publications, funded projects, or academic impactβ€”needed to support a strong case for a Best Researcher Award.

Guanwei Fan | Cardiovascular research | Best Researcher Award

Prof. Guanwei Fan | Cardiovascular research | Best Researcher Award

Prof. Guanwei Fan, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, China

Prof. Guanwei Fan, PhD, is a prominent researcher at the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, China. His research focuses on the molecular pharmacology of traditional Chinese medicine in cardiovascular diseases. Prof. Fan has received numerous accolades, including recognition as a national “WR” scientific and technological innovation talent and ranking among the top 2% of scientists globally in recent years. He has published extensively, contributing significantly to the understanding of cardiac repair and treatment methodologies. With a strong commitment to advancing traditional medicine, he continues to impact the field profoundly. πŸ“šβ€οΈ

 

Publication Profile

Scopus

Education

Prof. Guanwei Fan obtained his Doctoral degree from Tianjin University of Traditional Chinese Medicine (09/2005-06/2008) after earning his Master’s degree from the same institution (09/2002-07/2005). His academic background provides a solid foundation for his research endeavors in traditional Chinese medicine.

Research Direction

Prof. Fan specializes in the molecular pharmacology of traditional Chinese medicine, specifically in the context of cardiovascular diseases. His focus on this area demonstrates his commitment to bridging traditional practices with modern scientific methodologies, contributing valuable insights to the field of pharmacology.

Academic and Professional Achievements

Prof. Fan has garnered significant recognition for his contributions to research and innovation. He has been selected as a national “WR” scientific and technological innovation leading talent and enjoys special government subsidies from The State Council. He is also a national candidate for the Millions of Talents Project and has been recognized as a young and middle-aged scientific and technological innovation leading talent by the Ministry of Science and Technology. Additionally, he holds the title of the first Young Qihuang Scholar and has received multiple accolades, including Tianjin Outstanding Youth and Jinmen Medical Talents. Notably, he ranked among the top 2% of the world’s top scientists in the “Impact of 2022” and “Impact of 2021” lists.

Conclusion

Prof. Guanwei Fan is a highly suitable candidate for the Research for Best Researcher Award. His innovative approach to integrating traditional Chinese medicine with modern pharmacological research in cardiovascular diseases sets him apart as a leading figure in his field.

 

Publication Top Notes Β 

  • Zhang, K., Yin, Z., Chen, F., … Wang, Y., Fan, G. Omics-based pharmacological evaluation reveals Yuanhu Zhitong oral liquid ameliorates arthritis by regulating PKC/ERK/NF-ΞΊB signaling pathway. Journal of Ethnopharmacology, 2024. πŸ“–
  • Liu, Z., Bian, X., Li, L., … Liu, X., Fan, G. SENP1-Mediated HSP90ab1 DeSUMOylation in Cardiomyocytes Prevents Myocardial Fibrosis by Paracrine Signaling. Advanced Science, 2024. πŸ“–
  • Lin, J., Chen, Y., Luo, X., Fan, G. Research hotspots and trends of traditional Chinese and western medicine in treatment of heart failure with preserved ejection fraction. Chinese Traditional and Herbal Drugs, 2024. πŸ“–
  • Feng, C., Jiang, H., Fan, G., Li, L., Feng, J. Retrospective Study on the Efficacy of Qi Li Qiang Xin Jiao Nang in Reducing the Risk of Diuretic Resistance in Patients with Acute Decompensated Chronic Heart Failure. Chinese General Practice, 2024. πŸ“–
  • Shi, J., Yang, M.M., Yang, S., … Fan, G., Ma, C. MaiJiTong granule attenuates atherosclerosis by reducing ferroptosis via activating STAT6-mediated inhibition of DMT1 and SOCS1/p53 pathways in LDLRβˆ’/βˆ’ mice. Phytomedicine, 2024. πŸ“–
  • Li, Z., Lyu, C., Pan, G., … Zhang, B., Huang, Y., Fan, G. Strategies and methods for studying interaction between traditional Chinese and western medicine dominated by clinical benefit-risk signals. Chinese Traditional and Herbal Drugs, 2024. πŸ“–
  • Zhang, K., Ji, J., Li, N., Yin, Z., Fan, G. Integrated Metabolomics and Gut Microbiome Analysis Reveals the Efficacy of a Phytochemical Constituent in the Management of Ulcerative Colitis. Molecular Nutrition and Food Research, 2024. πŸ“–
  • Zhao, Y., Zheng, G., Yang, S., … Fan, G., Ma, C. The plant extract PNS mitigates atherosclerosis via promoting Nrf2-mediated inhibition of ferroptosis through reducing USP2-mediated Keap1 deubiquitination. British Journal of Pharmacology, 2024. πŸ“–
  • Wu, L.-L., Yang, B.-R., Meng, X.-Y., Fan, G.-W., Yang, B. Editorial: Artificial intelligence: new hope for critically ill cardiovascular patients. Frontiers in Medicine, 2024. πŸ“–
  • Zhang, L., Lin, J., Zhang, C., … Fan, G., He, F. Recent Advances in the Nanotechnology-Based Applications of Essential Oils. Current Nanoscience, 2024. πŸ“–

 

 

 

Xiangxiang Zheng | Cardiovascular Medicine | Best Researcher Award

Dr. Xiangxiang Zheng | Cardiovascular Medicine | Best Researcher Award

Dr. Xiangxiang Zheng, Jiangsu Province Hospital, China

Dr. Xiangxiang Zheng, a dedicated cardiac surgeon at Jiangsu Provincial People’s Hospital since 2008, specializes in minimally invasive treatments for heart valve diseases and stem cell therapy for myocardial infarction. With a PhD and over 300 cardiac surgeries performed annually, he is at the forefront of cardiovascular innovation. His notable publications include research on engineering extracellular vesicles for diagnosis and therapy, and comparing surgical techniques for atrial septal defect repair. Dr. Zheng’s work significantly contributes to advancing surgical practices and improving patient outcomes. He is 42 years old and married. β€οΈπŸ‘¨β€βš•οΈπŸ“š

 

Publication profile

Scopus


Professional Experience

Since 2008, Dr. Xiangxiang Zheng has been an esteemed cardiac surgeon in the Department of Cardiovascular Surgery at Jiangsu Provincial People’s Hospital. With over 300 cardiac surgeries performed annually, he has established himself as a leader in the field. Dr. Zheng specializes in minimally invasive treatments for heart valve diseases, which significantly reduce recovery time and improve patient outcomes. His expertise also extends to stem cell therapy for myocardial infarction, where he employs innovative techniques to enhance heart repair and regeneration. Dr. Zheng’s dedication to advancing cardiovascular care is evident through his hands-on surgical practice and commitment to exploring new methodologies in cardiac surgery. He continuously strives to improve surgical techniques and patient safety, making a lasting impact on the lives of those he treats. His contributions not only elevate the standard of care in his department but also serve as an inspiration to his colleagues and the medical community. πŸŒŸπŸ‘¨β€βš•οΈπŸ“ˆ

 

Research Focus

Dr. Xiangxiang Zheng’s research primarily focuses on cardiovascular surgery, particularly in innovative surgical techniques and therapies for heart diseases. His work emphasizes minimally invasive procedures, such as thoracoscopic surgeries for atrial septal defect repair, as well as advanced myocardial protection strategies during complex cardiac surgeries. Additionally, Dr. Zheng explores stem cell therapy and the engineering of extracellular vesicles for therapeutic applications, enhancing diagnosis and treatment methods in cardiology. His research also delves into the physiological impacts of surgical interventions on heart function and the progression of pulmonary arterial hypertension, contributing significantly to the field of cardiovascular medicine. πŸ₯πŸ“šβœ¨

 

Publication Top Notes

  • Engineering extracellular vesicles for diagnosis and therapy 🧬
    Fei, Z., Zheng, J., Zheng, X., Ren, H., Liu, G.
    Trends in Pharmacological Sciences, 2024.
    Cited by: 0
  • The Impact of Highly Selective Thoracic Sympathectomy on the Progression of Monocrotaline-induced Pulmonary Arterial Hypertension in Rats 🐭
    Liu, W., Men, C., Liu, Z., Zhang, L., Zheng, X.
    Journal of Physiological Investigation, 2024, 67(4), pp. 207-214.
    Cited by: 0
  • Triport Periareolar Thoracoscopic Surgery versus Right Minithoracotomy for Repairing Atrial Septal Defect in Adults πŸ’”
    Zheng, X.-X., Wang, Z.-Y., Ma, L.-Y., Qin, J.-W., Shao, Y.-F.
    Interactive Cardiovascular and Thoracic Surgery, 2021, 32(2), pp. 313-318.
    Cited by: 5
  • Comparison of Myocardial Protection Effect between Del Nido Cardioplegia and Cold Blood Cardioplegia in Complex Cardiac Surgery πŸ’‰
    Jiao, S.-Y., Liu, L., Ma, L.-Y., Zheng, X.-X., Qin, J.-W.
    Chinese Journal of Clinical Research, 2020, 33(6), pp. 807-810.
    Cited by: 0
  • Myocardial Protective Effect of Three Cardioplegia in Adult Valve Replacement πŸ’—
    Liu, H., Jiao, S.-Y., Ma, L.-Y., Zheng, X.-X., Qin, J.-W.
    Chinese Journal of Clinical Research, 2019, 32(6), pp. 775-778.
    Cited by: 1
  • Bilateral Superior Cervical Ganglionectomy Attenuates the Progression of Ξ²-Aminopropionitrile-induced Aortic Dissection in Rats πŸ§ͺ
    Liu, H., Zheng, X., Zhang, L., Shao, Y., Zhang, S.
    Life Sciences, 2018, 193, pp. 200-206.
    Cited by: 5
  • Cardiac Autotransplantation for Repair of Left Ventricular Rupture after Mitral Valve Replacement πŸ₯
    Ni, B., Zheng, X., Zhang, S., Shao, Y.
    Interactive Cardiovascular and Thoracic Surgery, 2017, 25(1), pp. 150-152.
    Cited by: 3
  • Three Circulating LncRNA Predict Early Progress of Esophageal Squamous Cell Carcinoma πŸ”¬
    Hu, H.-B., Jie, H.-Y., Zheng, X.-X.
    Cellular Physiology and Biochemistry, 2016, 40(1-2), pp. 117-125.
    Cited by: 68
  • High Expression of LncRNA PVT1 Promotes Invasion by Inducing Epithelial-to-Mesenchymal Transition in Esophageal Cancer πŸš€
    Zheng, X., Hu, H., Li, S.
    Oncology Letters, 2016, 12(4), pp. 2357-2362.
    Cited by: 85
  • Myxoid Fibrosarcoma of the Left Atrium and Ventricle in Pregnancy πŸ‘Άβ€οΈ
    Zhang, W., Zheng, X., Ni, B., Shao, Y., Zhang, S.
    Annals of Thoracic Surgery, 2014, 98(5), pp. 1818-1819.
    Cited by: 3